Doctors Revision

Tumour Markers: Types, Uses, Limitations and Clinical Interpretation

Text size
On this page

Overview

Tumour markers are measurable substances or molecular features associated with cancer. They may be produced by tumour cells, released because of tumour-related tissue injury, or expressed by normal cells in response to a tumour. Markers can support diagnosis, estimate prognosis, select treatment and monitor response, but most are neither sensitive nor specific enough to diagnose cancer alone or to screen the general population.

At a glance

  • Circulating markers: proteins, hormones, enzymes, antigens or nucleic acids measured in blood, urine or another body fluid.
  • Tissue markers: proteins or genetic features detected in tumour cells by immunohistochemistry, flow cytometry, cytogenetics or molecular testing.
  • Main uses: treatment selection, monitoring, prognosis, staging support and selected high-risk surveillance.
  • Major limitation: a raised marker may occur in benign disease, and a normal marker does not exclude cancer.
  • Best practice: interpret the result with history, examination, imaging, pathology and serial trends using the same laboratory method where possible.

Learning outcomes

The learner should be able to define tumour markers, classify circulating and tissue biomarkers, explain their clinical uses and limitations, recognise common markers and associated conditions, interpret trends safely and avoid inappropriate screening or diagnosis based on an isolated result.

1. Definition and classification

1.1 Circulating or fluid markers

These are measured in blood, urine, cerebrospinal fluid, pleural fluid or another specimen. Examples include alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (β-hCG), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA) and CA-125.

1.2 Tissue markers

These are detected in biopsy or surgical tissue. Immunohistochemistry identifies proteins such as oestrogen receptor, progesterone receptor, HER2, mismatch-repair proteins and PD-L1. Flow cytometry characterises haematological malignancies, while cytogenetics and sequencing detect rearrangements or mutations.

1.3 Molecular biomarkers

DNA, RNA, methylation, gene-fusion, copy-number and circulating tumour-DNA features can classify a tumour or identify a target. A biomarker can be diagnostic, prognostic, predictive or a combination.

2. What tumour markers can do

Scroll the table sideways on a smaller screen.

Clinical useHow the marker helpsWhat it cannot do alone
Support diagnosisRaises or lowers suspicion in a compatible clinical pictureUsually cannot establish cancer without tissue or definitive disease-specific evidence
Risk or surveillanceMonitors selected high-risk patients, such as AFP in chronic liver disease pathwaysDoes not replace imaging or specialist follow-up
PrognosisAssociates with tumour burden, subtype or expected behaviourCannot determine an individual outcome with certainty
Predictive treatment selectionIdentifies a target or pathway likely to respond to a therapyA marker does not guarantee response; resistance can develop
Response monitoringSerial fall may support treatment response; rise may signal progression or relapseEarly changes can reflect treatment-related cell death, inflammation or assay variation
Recurrence surveillanceTrend after definitive treatment may prompt imaging or reviewNot every recurrence raises a marker and not every rise is recurrence

3. Why isolated results mislead

  • False positive: benign inflammation, pregnancy, liver or kidney disease, smoking, menstruation, prostatitis, assay interference or another cancer raises the marker.
  • False negative: the tumour does not produce the marker, the disease burden is small, the specimen is poorly timed or the assay is insensitive.
  • Biological variation: levels fluctuate with physiology, hydration, organ clearance and tumour kinetics.
  • Analytical variation: different laboratories, platforms and reference ranges are not always interchangeable.
  • Lead-time and overdiagnosis: finding a marker earlier does not automatically improve survival or justify treatment.

A marker result should be interpreted as a probability modifier. Ask: “What is the pre-test probability, what benign causes are plausible, and what confirmatory test will change management?”

4. Common circulating tumour markers

Scroll the table sideways on a smaller screen.

MarkerCommon associationsBenign/non-cancer causes and cautionsTypical clinical use
AFPHepatocellular carcinoma; non-seminomatous germ-cell tumoursPregnancy, chronic hepatitis, cirrhosis and liver injury; some cancers do not raise AFPSurveillance/diagnostic support in selected liver-risk pathways; germ-cell tumour assessment
β-hCGGestational trophoblastic disease; some germ-cell tumoursPregnancy, pituitary hCG, assay interference and rare tumoursDiagnosis, staging and response monitoring with imaging and pathology
PSAProstate cancerBenign prostatic enlargement, prostatitis, urinary retention, ejaculation and instrumentationRisk assessment, selected screening after shared decision-making, treatment/recurrence monitoring
CEAColorectal and some pancreatic, gastric, breast and lung cancersSmoking, inflammation, liver disease and benign gastrointestinal diseaseBaseline and serial monitoring, especially after colorectal cancer treatment
CA-125Epithelial ovarian and related cancersMenstruation, pregnancy, endometriosis, pelvic inflammation, liver disease and effusionsMonitoring selected ovarian cancers; not a stand-alone population screening test
CA 19-9Pancreatic and biliary cancersCholestasis, cholangitis, pancreatitis and Lewis-antigen non-expressionMonitoring in a compatible diagnosis; not diagnostic alone
CA 15-3/CA 27-29Breast cancer and some other adenocarcinomasBenign breast/liver disease and other cancersSelected treatment/recurrence monitoring; not general screening
CalcitoninMedullary thyroid carcinomaRenal disease, other neuroendocrine conditions and assay variationDiagnosis and surveillance in selected patients/families
ThyroglobulinDifferentiated thyroid cancer after thyroid tissue removal/ablationResidual benign thyroid tissue and anti-thyroglobulin antibodiesRecurrence surveillance with antibody interpretation
LDHLymphoma, leukaemia, germ-cell tumours and high tumour burdenTissue injury, haemolysis, liver disease, infection and muscle injuryPrognostic/risk stratification support, not tumour-specific diagnosis

5. Tissue and molecular biomarkers

5.1 Breast and other solid tumours

  • Oestrogen and progesterone receptors: predict potential benefit from endocrine therapy.
  • HER2: overexpression or amplification may support HER2-targeted treatment; test methods and thresholds matter.
  • PD-L1: may inform immunotherapy in selected cancers, but scoring is tumour-specific.
  • Mismatch-repair proteins/microsatellite instability: identify repair deficiency and may predict immunotherapy response or inherited Lynch syndrome risk.

5.2 Haematological malignancy

Flow cytometry, immunophenotyping, cytogenetics and molecular tests distinguish leukaemia and lymphoma lineages, classify risk and detect measurable residual disease. Results must be interpreted with blood film, marrow morphology and clinical findings.

5.3 Actionable genetic biomarkers

Specific mutations or fusions may guide targeted therapy in lung, colorectal, melanoma, thyroid, breast and other cancers. A negative result may reflect tumour heterogeneity, inadequate tissue or assay limitations. A tissue biomarker is usually a somatic finding unless germline testing confirms inherited risk.

6. Interpreting a tumour-marker result

  1. Confirm the indication: Why was it ordered—symptoms, known cancer, high-risk surveillance or treatment planning?
  2. Review pre-test probability: Age, symptoms, examination, imaging, family history, exposures and prior cancer.
  3. Check the specimen and method: timing, fasting or pregnancy status where relevant, laboratory reference range and assay platform.
  4. Look for benign explanations: infection, inflammation, obstruction, organ failure, smoking, menstruation, pregnancy or recent instrumentation.
  5. Use serial trends: compare the same assay where possible; consider half-life and expected treatment kinetics.
  6. Confirm with imaging, pathology or specialist review: do not treat an isolated number as a diagnosis.

7. Kinetics and serial monitoring

After tumour treatment, a marker may fall according to its biological half-life. A slow decline, plateau or second rise can suggest residual or recurrent disease, but timing matters. Surgical manipulation, chemotherapy-related cell lysis, infection and organ dysfunction can cause transient changes. The marker should be interpreted alongside symptoms, examination and imaging.

Use the same laboratory method whenever possible. Record dates, treatments, pregnancy status, organ function and relevant procedures. A small change near the assay’s analytical variation may not be clinically meaningful.

8. Screening limitations

Most circulating tumour markers do not work well for screening asymptomatic people because they miss cancers and produce false positives. Screening tests must demonstrate benefit, acceptable harms and a clear pathway for confirmatory diagnosis. Established screening programmes—such as cervical, breast or colorectal pathways—should not be replaced by unvalidated panels.

Selected markers have a role in high-risk surveillance or a specific clinical context. For example, AFP may be used within an appropriate chronic-liver-disease surveillance programme, and PSA decisions require shared decision-making that considers age, risk, benefits and harms.

9. Marker-specific pitfalls

AFP

AFP can rise in pregnancy and active hepatitis or cirrhosis. A normal AFP does not exclude hepatocellular carcinoma, and a high result does not prove it. Combine with liver imaging and specialist assessment.

β-hCG

Always consider pregnancy before interpreting β-hCG. Germ-cell tumours may produce β-hCG or AFP; seminoma classically does not produce AFP. False-positive low-level results can occur from assay interference or pituitary production.

PSA

PSA is prostate-specific, not cancer-specific. Benign enlargement, prostatitis, retention, ejaculation and instrumentation can alter values. Interpret age, prostate volume, symptoms, examination and serial change according to local guidance.

CA-125 and CA 19-9

Pelvic inflammation, menstruation, endometriosis, cholestasis, cholangitis and pancreatitis can raise these markers. A raised result requires clinical correlation and imaging, not automatic cancer labelling.

CEA

Smoking and benign liver or bowel inflammation can elevate CEA. It is most useful as a baseline and trend in a known, marker-producing cancer rather than as a general screening test.

10. Tumour markers in emergencies

Do not delay resuscitation

  • Shock, airway obstruction, sepsis, severe bleeding, spinal cord compression and metabolic crises require immediate ABCDE management.
  • Ordering a marker should never delay imaging, blood products, antibiotics, decompression or specialist referral.

Urgent interpretation

  • Very high β-hCG or AFP with a mass may support germ-cell tumour evaluation, but tissue/imaging and haemodynamic status guide action.
  • High calcium, LDH or uric acid may indicate tumour burden or treatment-related lysis, but each has non-cancer causes.

Safety

  • Document pregnancy status, renal/liver function, transfusion and recent procedures.
  • Communicate critical results directly and arrange follow-up for abnormal results that are not immediately diagnostic.

11. Case applications

Case 1: Raised CA 19-9 with jaundice

A patient with obstructive jaundice has a high CA 19-9. Cholestasis and cholangitis can elevate the marker, so manage the obstruction/infection and obtain appropriate imaging. Reassess after resolution rather than diagnosing pancreatic cancer from one value.

Case 2: AFP in chronic hepatitis

A patient with chronic hepatitis B has a rising AFP. The result increases concern but does not prove hepatocellular carcinoma. Follow the liver-surveillance pathway with ultrasound or cross-sectional imaging and specialist review.

Case 3: PSA after instrumentation

A PSA is measured shortly after urinary retention and catheterisation. These events can affect PSA. Record timing, treat the acute problem and repeat or investigate according to local prostate guidance rather than making an immediate cancer diagnosis.

12. Reporting and communication

  • State the marker, value, units, reference range, assay method and date.
  • Explain what the result can and cannot establish.
  • Use “abnormal marker” rather than “cancer” until the diagnosis is confirmed.
  • Give a clear plan for confirmatory testing, referral and repeat measurement.
  • Discuss anxiety, false positives and the possibility of a normal marker in cancer.

Quick self-test

  1. What are the main clinical uses of tumour markers?
  2. Why can a normal marker fail to exclude cancer?
  3. Name three benign causes of a raised marker.
  4. Which tissue biomarkers can guide targeted therapy?
  5. Why should tumour markers not be used as general population screening tests?
Answers
  1. Support diagnosis, prognosis, treatment selection, response monitoring, recurrence surveillance and selected high-risk surveillance.
  2. Some tumours do not produce the marker, the burden may be small, or the assay may be insensitive.
  3. Examples include pregnancy, inflammation/infection, liver or kidney disease, smoking, menstruation, prostatitis, cholestasis and assay interference.
  4. Examples include HER2, hormone receptors, mismatch-repair/MSI, PD-L1 and actionable mutations/fusions.
  5. Most lack adequate sensitivity and specificity, producing false negatives, false positives, overdiagnosis and unnecessary procedures.

References and further reading

Lesson map

Further reading

For deeper study, compare this lesson with current guidance and standard references from recognised medical and public-health organisations.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top